GlassScriptPhysician profile
Sanford M Wolfe
NPI 1255390233
$20,814.76
in general payments reported to CMS, 2019-2025
32 companies · $849 in 2025
The $849 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $1,244 · 2021: $2,215 · 2022: $2,181 · 2023: $2,683 · 2024: $1,483 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,659 · Education: $181 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,659.42 |
| Education | $180.82 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $9,282.80 | 2019-2024 | |
| Abbvie INC. | $3,219.12 | 2019-2025 | Rinvoq |
| Amgen INC. | $2,148.80 | 2019-2025 | Evenity, Enbrel, Prolia |
| Novartis Pharmaceuticals Corporation | $1,201.55 | 2019-2023 | |
| Ucb, INC. | $1,091.57 | 2020-2024 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,081.83 | 2019-2024 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $367.18 | 2020-2023 | Taltz |
| Glaxosmithkline, LLC. | $315.09 | 2020-2024 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $303.90 | 2021-2023 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $278.80 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $256.25 | 2020-2023 | Acthar |
| Horizon Therapeutics Plc | $236.44 | 2019-2021 | |
| Radius Health, INC. | $229.04 | 2019-2024 | Tymlos |
| Janssen Scientific Affairs, LLC | $124.98 | 2022 | |
| Mallinckrodt Enterprises LLC | $112.44 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $97.51 | 2023-2024 | Idacio |
| Medexus Pharma, INC. | $97.00 | 2019 | |
| Ani Pharmaceuticals, INC. | $96.90 | 2022-2023 | Purified Cortrophin Gel |
| Genentech USA, INC. | $86.14 | 2019-2024 | Actemra, Rituxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.57 | 2019-2023 | Ofev |
| Genzyme Corporation | $38.54 | 2020-2023 | |
| Ultragenyx Pharmaceutical INC. | $21.65 | 2021 | |
| Organon LLC | $20.48 | 2024 | |
| Sobi, INC | $20.03 | 2024 | |
| Celltrion USA INC. | $15.83 | 2023 | Yuflyma |
| Regeneron Healthcare Solutions, INC. | $12.89 | 2019 | |
| Celgene Corporation | $12.43 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanford Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.